| J Pharm Sci Emerg Drugs |
| Bio-Equivalence of Ciprofloxacin 500mg |
Khalid Aftab and Sidrah Khan |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Biomimetic HPLC property measurements to estimate human in vivo distribution and tissue binding of drug discovery compounds |
Valko KL |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Biosimilar assays: Guiding principles (PK, ADA and Nab) for a Bioanalytical scientist for a one or two assay choice |
Aparna Kasinath |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Biosimilars: challenges in safety and risk management |
Asif Mahmood |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Challenges for biosimilar drug development , scale up & higher scale manufacturing : Developed and developing country landscape. |
Sumant Chaubey |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Challenges in quality control of biosimilars in India: Role of National Institute of Biologicals |
Subhash Chand, J P Prasad, Surinder Singh |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Coronary flow regulation by adenosine it’s signaling |
S Jamal Mustafa |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Development of a male contraceptive from traditionally used Indian medicinal plants |
Pratap Chand Mali |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Direct evidence of viral infection and mitochondrial alterations in the brain of fetuses at high risk for schizophrenia |
Segundo Mesa Castillo |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Food and nutrition security and its association with women and children health of deprived community |
Ramu |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Growth potential of biosimilars in emerging countries |
Md Abu Zafor Sadek |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Harnessing the power of the network to deliver biosimilar medicine trials |
Divya Chadha Manek |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| How to address immunogenicity in the development of a rare disease biosimilar |
Candida Fratazzi |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| How to increase Biosimilar access and commercialization success |
James Harris |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Liquid –liquid extraction method developed for thymoquinone from seed powder of Nigella Sativa, characterized it by UV-spectrophotometer |
Mohamad Taleuzzaman, Sadaf Jamal Gilani and Sayed Sarim Imam |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Navigating the Legal And Ip Challenges To Biosimilar Market Entry |
Joanna T Brougher |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Newly approved antimicrobial agents: where do they belong? |
Jonathan Cho |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Optimizing Clinical trials as part of the totality of data to support the marketing approval of biosimilars |
Cecil J Nick |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Pharmacokinetics and dosage regimen of ciprofloxacin following single intramuscular administration in nili/ravi buffalos |
Zahid Iqbal and Ijaz Javed |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Prevalence of intestinal parasitic infections and their associations with anthropometric measurements of school children in selected primary schools, Wukro Town, Eastern Tigray, Ethiopia |
Eleni Kidane |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Thaumatin protein from African Thaumatococcus danielli in formulated organic drink and snack significantly improved the nutritional status in wistar rats |
Oyebamiji Emmanuel Aanuoluwapo |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| The regulatory framework for similar biotherapeutic products in Cuba |
Y Hechavarria Nunez, R Perez Massipe, L Martinez Munoz, D Orta Hernandez and V Perez Rodriguez |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| The US-FDA interchangeability guidance for biosimilars |
Michel Mikhail |
|
PDF |
HTML
|
| J Pharm Sci Emerg Drugs |
| Treatment of metastatic or high-risk solid cancer patients by targeting immune system and/or tumor burden: Six cases report |
Andrea Nicolini, Paola Ferrari and Angelo Carpi |
|
PDF |
HTML
|
